Aug 22, 2017 Cellectar Biosciences Announces Significant PDC Platform Advancement; Demonstrates Potential to Improve Therapeutic Window Learn More
Aug 14, 2017 Cellectar Biosciences Reports Second Quarter 2017 Financial and Corporate Performance Learn More
Aug 8, 2017 Cellectar Biosciences’ CLR 131 Achieves Overall Survival of Greater Than 22 Months in Advanced Multiple Myeloma Patients Learn More
Aug 3, 2017 Cellectar Biosciences to Host Conference Call on August 14, 2017 to Report Second Quarter 2017 Financial Results and Corporate Performance Learn More